rapid enzyme immunoassay (eia) test c. diff quick chek complete (TechLab Inc)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

TechLab Inc rapid enzyme immunoassay (eia) test c. diff quick chek complete
Rapid Enzyme Immunoassay (Eia) Test C. Diff Quick Chek Complete, supplied by TechLab Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/rapid+diff-quick/c++diff+quick+check+complete+enzyme+immunoassay/pm33783664-44-15-25
Average 90 stars, based on 1 article reviews

rapid enzyme immunoassay (eia) test c. diff quick chek complete - by Bioz Stars, 2026-09

90/100 stars

Images

Membrane:

Article Title: Predictive value of fecal calprotectin and lactoferrin levels for negative outcomes in Clostridioides difficile infection.
Article Snippet: Purpose We investigated the role of fecal calprotectin (FC) and lactoferrin (FL) as predictive biomarkers in Clostridioides difficile infection (CDI).. Methods We assembled a prospective cohort including all patients with a laboratory-confirmed CDI diagnosis between January and December 2017.. FL and FC levels were measured at diagnosis by commercial ELISA and EIA kits.

Enzyme-linked Immunosorbent Assay:

Article Title: Clostridioides difficile infection in patients with and without COVID-19 during the pandemic: a retrospective cohort study from a tertiary referral hospital.
Article Snippet: 31 Objectives: This study aims to detect the prevalence and specific characteristics of 32 Clostridioides difficile infection (CDI) during the COVID-19 pandemic.. 33 Methods: In this retrospective observational study, conducted in a tertiary hospital in 34 Greece between May 2021 and October 2022, patients with CDI from COVID-19 and Internal 35 Medicine wards were enrolled and compared based on epidemiological and disease36 associated data.. 37 Results: In total, 4322 patients were admitted, and 435 samples for CDI were analyzed, with 38 104/435 (23.9%) sample positivity and 2.4% prevalence.

Diff-Quik:

other:

Article Title: In vitro Activity of Dalbavancin and Fourteen Other Antimicrobial Agents against Toxigenic Clostridioides difficile Clinical Isolates in a Greek Tertiary-Care Hospital
Article Snippet: Stool samples obtained from patients with suspected CDI were tested using an immunoenzymatic assay (C. diff Quik Chek Complete, TechLab, Blacksburg, VA, USA) for the simultaneous detection of glutamate dehydrogenase and toxins A + B according to the manufacturer’s instructions.

Article Title: Three stages of laboratory stewardship in improving appropriate Clostridioides difficile testing in a community-based setting
Article Snippet: Starting in March 2022, initial C. difficile detection was completed by NAAT, and positive NAAT tests were confirmed by toxin EIA (TechLab, C. diff Quick Chek Complete, Blacksburg, VA).

Article Title: Clostridioides difficile hypervirulent strain ST1 isolated from clinical stool specimens obtained from three Provinces in South Africa.
Article Snippet: This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record.. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article.. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Article Title: Prevalence of Enteric Pathogens and Antibiotic Resistance: Results of a Six-Year Active Surveillance Study on Patients Admitted to a Teaching Hospital
Article Snippet: Results were available within 1 h. For the diagnosis of C. difficile toxin A/B-producing strains, the rapid membrane enzyme immunoassay C. DIFF QUIK CHEK COMPLETE ® test (TechLab, Blacksburg, VA, USA) was also performed so as to detect both toxins’ A/B production and glutamate dehydrogenase (GDH), according to the manufacturer’s instructions.

Article Title: Epidemiology of Clostridioides difficile PCR ribotype 181 after the COVID-19 pandemic in Northern Greece.
Article Snippet: All stool samples were tested directly for both glutamate dehydrogenase (GDH) and toxins A/B (Tox A/B) of C. difficile by an enzyme immunoassay (EIA; C. DIFF QUICK CHECK COMPLETE, Alere/TechLab, Blacksburg, USA) as part of a two-step algorithm for CDI testing.

Review